Seoul
Chief MD, Gangnam
Duk-ha Kim
The trust our patients have placed in this clinic was built on conviction and principle. We intend to hold to both, unchanged, through the next hundred years.
Botulinum toxin menu guide
Wrinkle Toxin
Wrinkle toxin is a menu category rather than a single product: a Korean clinic menu can list many separate botulinum toxin type A entries, often grouped by country of origin. Units are defined per product and the labels state they cannot be converted between products, and approved uses differ by country.
- What it is
- Menu category covering several botulinum toxin type A products
- Units
- Product-specific; labels state they are not interchangeable
- Approved uses
- Differ by product and by country of approval
- Label warning
- U.S. boxed warning on distant spread of toxin effect
Does a wrinkle toxin menu refer to one product?
No. It is a category, and a single clinic menu in Korea can carry dozens of separate entries that each map to a different botulinum toxin type A product. Menus here are often grouped by country of origin rather than by brand name, so the menu wording alone does not tell you what will be injected. Each product named on this page is approved on its own record: BOTOX Cosmetic, Dysport, Xeomin and Jeuveau under the U.S. FDA, and Nabota, Meditoxin and Lidztox under the Korean MFDS.
Sources: FDA label — BOTOX Cosmetic (AbbVie, rev. 2024-10)MFDS drug product record — Nabota 50 U (Daewoong, approved 2015-01-08)MFDS drug product record — Meditoxin (Medytox, approved 2006-03-16)MFDS drug product record — Lidztox 50 U (Huons BioPharma, approved 2021-06-15; export name Hutox)
What does an origin label such as domestic or German actually name?
It names a claimed country of manufacture, not a product. Among the products documented on this page, the one made in Germany is Xeomin, from Merz. The origin wording on any individual clinic menu is not verified here, and the other menu entries are not documented on this page, so treat origin labels as a prompt to ask for the exact product name and to confirm it against the vial and the approval record before you agree to the injection.
Sources: FDA label — XEOMIN (Merz, rev. 2026-06)MFDS drug product record — Nabota 50 U (Daewoong, approved 2015-01-08)
Can you compare the number of units between two products?
No, and each label says so in its own words. The U.S. BOTOX Cosmetic label states that its Units "cannot be compared to nor converted into Units of any other botulinum toxin products", and the Dysport label states that "The potency units of DYSPORT are not interchangeable with other preparations of botulinum toxin products". The Xeomin and Jeuveau labels carry the same kind of statement. A larger unit number on one quote therefore does not mean more treatment than a smaller number quoted for a different product, and none of this says that one product is stronger than another.
Sources: FDA label — BOTOX Cosmetic (AbbVie, rev. 2024-10)FDA label — DYSPORT (Ipsen, rev. 2023-09)FDA label — XEOMIN (Merz, rev. 2026-06)FDA label — JEUVEAU (Evolus, mfd. Daewoong Korea, rev. 2023-04)
Are the approved uses the same in every country?
No, and they differ by product as well. In the United States, BOTOX Cosmetic is approved for glabellar lines, lateral canthal lines, forehead lines and platysma bands; Jeuveau is approved for glabellar lines only; and Dysport covers cervical dystonia, glabellar lines in adults younger than 65, and spasticity from age 2. In Korea, the MFDS record for Nabota covers glabellar lines in adults aged 20 to 65, upper-limb spasticity after stroke, lateral canthal lines in adults aged 18 to 65, blepharospasm, and masseter hypertrophy in adults aged 18 to 65 — an indication that does not appear in the U.S. labels cited here. Read every approval statement together with the country it belongs to.
Sources: FDA label — BOTOX Cosmetic (AbbVie, rev. 2024-10)FDA label — DYSPORT (Ipsen, rev. 2023-09)FDA label — JEUVEAU (Evolus, mfd. Daewoong Korea, rev. 2023-04)MFDS drug product record — Nabota 50 U (Daewoong, approved 2015-01-08)
How does the injection act on a muscle that creates expression lines?
It blocks the release of acetylcholine at the neuromuscular junction. Section 12.1 of the U.S. BOTOX Cosmetic label describes the toxin cleaving SNAP-25, a protein the nerve terminal needs in order to release acetylcholine, so the treated muscle receives less signal to contract; the Xeomin label describes the same enzymatic cleavage of SNAP25. The mechanism acts on nerve signalling, so it is not a filling or a tissue-removing procedure. Xeomin is also described on its label as the neurotoxin without complexing proteins, a 150 kDa preparation — a formulation difference between products, not a ranking between them.
Sources: FDA label — BOTOX Cosmetic (AbbVie, rev. 2024-10)FDA label — XEOMIN (Merz, rev. 2026-06)
What did the placebo-controlled trials actually measure?
They measured responder rates on fixed assessment days, not a duration expressed in months. Section 14 of the U.S. BOTOX Cosmetic label describes two randomized, multicenter, double-blind, placebo-controlled trials in which 405 participants received a single 20-Unit treatment and 132 received placebo. At Day 30, investigator assessment counted 80% (325/405) responders against 3% (4/132) on placebo, and participant self-assessment counted 89% (362/405) against 7% (9/132). At Day 120, the investigator-assessed figure was 25% (102/403) against 2% (2/128). Those are trial results measured on defined days under a defined protocol; they are not a promise of how long an individual result will last.
How long does the effect last?
The trial figures above already show a decline rather than a fixed number: investigator-assessed responders fell from 80% (325/405) at Day 30 to 25% (102/403) at Day 120, all measured after a single 20-Unit BOTOX Cosmetic treatment. That trajectory belongs to one product at one dose in one trial, and the label states its Units cannot be compared to nor converted into Units of any other botulinum toxin product, so the same two assessment days do not carry over to a different product or a different unit count. No label cited on this page turns that into a months-long guarantee for an individual patient. What actually shapes how long a given result holds — the muscle treated, the dose placed there, and each person’s own response — is a clinical question, so raise it at the injection itself: which product and unit count are being used, how the injecting clinician expects that specific combination to behave over time, and what interval they plan before reassessing.
What safety warning is printed on the label, and who cannot be treated?
The U.S. BOTOX Cosmetic label carries a boxed warning headed "WARNING: DISTANT SPREAD OF TOXIN EFFECT", covering effects that may spread from the injection site hours to weeks after injection and produce symptoms of botulinum toxicity, including swallowing and breathing difficulties that can be life threatening. The same label lists two contraindications: hypersensitivity to any botulinum toxin preparation, and infection at the proposed injection site. Contraindications are not identical across products — the Dysport label additionally contraindicates people with hypersensitivity to cow’s milk protein, which is why the product name has to be settled before the safety questions can be answered.
Sources: FDA label — BOTOX Cosmetic (AbbVie, rev. 2024-10)FDA label — DYSPORT (Ipsen, rev. 2023-09)
Why does one product appear under more than one name?
Because an export name and a domestic approval name are different things. The Korean record for Meditoxin also lists export names such as Neuronox and Siax, and Hutox is an export name whose Korean approval name is Lidztox, approved for Huons BioPharma on 15 June 2021. In the other direction, Jeuveau is approved in the United States and its label names Daewoong Pharmaceutical in Korea as the manufacturer. A name you met abroad and a name on a Korean menu may be the same product or different ones, and only the approval name settles which.
Sources: MFDS drug product record — Meditoxin (Medytox, approved 2006-03-16)MFDS drug product record — Lidztox 50 U (Huons BioPharma, approved 2021-06-15; export name Hutox)FDA label — JEUVEAU (Evolus, mfd. Daewoong Korea, rev. 2023-04)
Does an approval in one country carry over to another?
No. Japan lists a cosmetic-use brand, Botox Vista, with the PMDA separately from the therapeutic Botox brand; this page does not reproduce its approved indication wording, so nothing here should be read as a Japanese indication. In China, a 2020 notice from the Beijing Medical Products Administration set out the type A botulinum toxin products legally handled there as the domestically produced Hengli and the imported Botox, and Korean-made products are not on that list. Neither point says anything about what is legally approved in Korea; each describes the regulatory position in that country.
Sources: PMDA listing — Botox Vista for injection (AbbVie GK)Beijing Medical Products Administration — list of businesses legally handling type A botulinum toxin (2020-02-24)
What should you confirm before the injection is given?
Confirm the exact product name first, then the number of units per area, then the areas being treated — in that order, because a unit number only means something once the product is named. Ask which regulator approved that product for that area, who performs the injection, and whom to contact if symptoms appear later. Disclose any previous botulinum toxin treatment and its date, hypersensitivity to any botulinum toxin preparation, product-specific allergies such as cow’s milk protein for Dysport, any infection at the injection site, neuromuscular conditions, current medicines, and pregnancy or breastfeeding.
Sources: FDA label — BOTOX Cosmetic (AbbVie, rev. 2024-10)FDA label — DYSPORT (Ipsen, rev. 2023-09)
Which regulator approved which product, for what?
These are separate products with separate approval records, not tiers of one treatment. Use this table to line up which country approved a product and for which uses, and note that unit counts do not translate from one row to another.
| Product | Regulator and record | Approved uses in that country | Units and contraindication notes |
|---|---|---|---|
| BOTOX Cosmetic | U.S. FDA — AbbVie label, rev. 2024-10 | Glabellar lines, lateral canthal lines, forehead lines, platysma bands | Label states Units cannot be compared to nor converted into Units of any other botulinum toxin product; contraindicated in hypersensitivity to any botulinum toxin preparation and infection at the injection site |
| Dysport | U.S. FDA — Ipsen label, rev. 2023-09 | Cervical dystonia; glabellar lines in adults younger than 65; spasticity from age 2 | Potency units stated as not interchangeable with other botulinum toxin preparations; contraindications include hypersensitivity to cow’s milk protein |
| Xeomin | U.S. FDA — Merz label, rev. 2026-06 | Approved uses include glabellar lines, forehead lines and lateral canthal lines | Units stated as not interchangeable with other products; described as the neurotoxin free from complexing proteins (150 kDa) |
| Jeuveau | U.S. FDA — Evolus label, rev. 2023-04 | Glabellar lines only | Units stated as not interchangeable with other products; manufactured by Daewoong Pharmaceutical in Korea |
| Nabota | Korea MFDS — Daewoong, approved 2015-01-08 | Glabellar lines (20-65), upper-limb spasticity after stroke, lateral canthal lines (18-65), blepharospasm, masseter hypertrophy (18-65) | A Korean approval; the masseter indication does not appear in the U.S. labels cited here |
| Meditoxin | Korea MFDS — Medytox, approved 2006-03-16 | Blepharospasm, equinus deformity in pediatric cerebral palsy, glabellar lines (20-65), upper-limb spasticity | Listed with export names including Neuronox and Siax, so one product can appear under several names |
| Lidztox | Korea MFDS — Huons BioPharma, approved 2021-06-15 | Glabellar lines and lateral canthal lines (19-65), upper-limb spasticity (19 and over) | Hutox is an export name; Lidztox is the Korean approval name to quote when checking the record |
This table maps approvals from the labels cited on this page. It is not a ranking, not an efficacy comparison, and not a statement that any two products can be exchanged at the same number of units.
Sources: FDA label — BOTOX Cosmetic (AbbVie, rev. 2024-10)FDA label — DYSPORT (Ipsen, rev. 2023-09)FDA label — XEOMIN (Merz, rev. 2026-06)FDA label — JEUVEAU (Evolus, mfd. Daewoong Korea, rev. 2023-04)MFDS drug product record — Nabota 50 U (Daewoong, approved 2015-01-08)MFDS drug product record — Meditoxin (Medytox, approved 2006-03-16)MFDS drug product record — Lidztox 50 U (Huons BioPharma, approved 2021-06-15; export name Hutox)
Medical care at Abijou
Care is provided by the medical team at the branch you select. These clinicians lead the three branches linked from this guide; confirm the doctor assigned to your visit with that branch.
Chief MD, Myeongdong
Cheol-su Yoon
I want to be thinking about how the patient feels right up to the last moment of the procedure.
Chief MD, Hongdae
Jae-wook Kim
I will give my best with the attentiveness to catch even the smallest change.
Listed branch medical team — not a medical-review byline for this article.
Frequently asked questions
Is wrinkle toxin a brand name?
No, it is a menu heading. Behind it sit several botulinum toxin type A products, each with its own approval record, its own approved areas and its own unit definition. The name you need for any comparison is the product name, not the menu heading.
Do menu words like premium or imported tell me which product I will receive?
No. Those words describe how a clinic has grouped its own menu, not a regulatory category. Among the products documented on this page, only Xeomin from Merz is identified as German-made. Ask which product the entry refers to and check the name against the approval record.
Does the injection fill the line, or relax the muscle?
It acts on nerve signalling rather than volume. The toxin cleaves SNAP-25, the protein a nerve terminal needs to release acetylcholine, so the treated muscle receives less contraction signal; the Xeomin label describes the same enzymatic cleavage of SNAP25. Nothing is added to the skin, so it is a different kind of procedure from a filler.
One clinic quotes 50 units and another quotes 100 units — is the second one twice the treatment?
Not necessarily, because unit counts only compare within the same product. The U.S. BOTOX Cosmetic label states its Units cannot be compared to nor converted into Units of any other botulinum toxin product, and Dysport, Xeomin and Jeuveau carry equivalent statements. Until both quotes name the same product, the two numbers are measured on different scales.
A clinic offers jaw-line injections into the masseter — is that an approved use in the United States too?
It is approved in Korea, not in the U.S. labels cited here. The Korean MFDS record for Nabota lists masseter hypertrophy in adults aged 18 to 65, while the U.S. BOTOX Cosmetic label covers glabellar lines, lateral canthal lines, forehead lines and platysma bands and does not list that use. Approvals are decided country by country, so ask which national approval applies to the product in front of you.
Is Hutox the same product as Lidztox?
Hutox is an export name and Lidztox is the Korean approval name for the product from Huons BioPharma, approved on 15 June 2021. Meditoxin is another example, listed with export names such as Neuronox and Siax. When you check a record or compare quotes, quote the approval name.
How much does the injection hurt?
The labels cited on this page do not report a pain score, so this page cannot put a number on it. It is a needle procedure, and whether topical anaesthetic or ice is used is a clinic decision — ask what they use and how long the appointment takes.
When would a change be visible, and is there downtime?
The evidence cited here does not answer that as a schedule. The placebo-controlled trials in the U.S. BOTOX Cosmetic label assessed participants at Day 30 and Day 120 rather than tracking onset day by day, so the label data supports responder rates on those days and not an onset date or a recovery timetable. Follow the aftercare instructions from the clinic that treated you.
How often is the treatment repeated?
The trials described in the U.S. BOTOX Cosmetic label evaluated a single 20-Unit treatment with assessments at Day 30 and Day 120; they do not set a re-treatment schedule. The interval is a clinical decision based on the product used, the area and your own history, so ask the injecting clinician rather than assuming a fixed cycle.
Who cannot have this treatment?
The answer depends on the product. The U.S. BOTOX Cosmetic label lists two contraindications: hypersensitivity to any botulinum toxin preparation, and infection at the proposed injection site. The Dysport label additionally contraindicates hypersensitivity to cow’s milk protein. Neuromuscular conditions, current medicines, pregnancy and breastfeeding all need to be disclosed and reviewed in person.
Which symptoms after the injection need urgent medical attention?
Swallowing or breathing difficulty needs immediate medical attention. The boxed warning on the U.S. BOTOX Cosmetic label, headed "WARNING: DISTANT SPREAD OF TOXIN EFFECT", describes effects spreading from the injection site hours to weeks after injection and producing symptoms of botulinum toxicity, including swallowing and breathing difficulties that can be life threatening. Contact the treating clinic as well, and tell any emergency clinician which product was injected and when.
Can I get the same product again when I go home?
Not automatically, because approval and legal distribution are national. A 2020 notice from the Beijing Medical Products Administration set out the type A botulinum toxin products legally handled in China as the domestic Hengli and the imported Botox, with Korean-made products absent from that list, and Japan lists a separate cosmetic-use brand, Botox Vista, with the PMDA. Ask which product was used in Korea and check what is approved where you live before you plan a repeat.
How do I compare two quotes from different clinics?
Line up the product name first, then the units per area, the areas included and whether the quote is one appointment or several. Unit counts from two different products are not a like-for-like comparison, so a quote that names only a menu heading cannot be compared at all. This page carries no prices; ask each clinic to state the current amount and what it includes.
Who is this suitable for, and can it be done on a short trip?
Suitability is decided at an in-person consultation, not from a menu. Tell the clinic your travel dates, the date and product of any previous botulinum toxin treatment, your allergies, neuromuscular conditions, current medicines, and any pregnancy or breastfeeding. Also ask what happens if you need follow-up after you have left the country.
How Abijou works
We started in Gangnam in 2006 and the network now runs 17 branches across Korea. The line we work to is skin transformation woven into everyday life — care you can keep up with, rather than one dramatic change.
- Across the 17 branches in Seoul, Gyeonggi, Incheon and Busan: over 1,000 medical professionals and more than 350 certified medical devices
- Authentic products only, in appropriate amounts — the treatment is fitted to the condition, not to a package
- Prices are quoted from each branch’s published price list as it stands
Contact and location
- Phone
- 1544-0377
Free Consultation
Booking happens at the branch
There is no inquiry form on this page. Once you have picked a branch above, open that branch’s site or the official reservation center and choose a time yourself.
- No deposit and no online prepayment — everything is paid at the visit
- Per-treatment prices are published for each branch on the official reservation center
- English, Japanese and Chinese are supported alongside Korean